The safety of insulin lispro was compared with that of regular human insulin of recombinant DNA origin (Humulin R, Lilly), with special emphasis on the development and progression of the chronic complications of diabetes mellitus in relation to insulin therapy. Ten clinical trials of 3634 patients with type 1 and type 2 diabetes mellitus were analyzed. The primary focus was treatment-emergent adverse events, and the secondary focus was the development and progression of the chronic complications of diabetes. The evaluations were based on pertinent laboratory values, predetermined disease-specific COSTART (coding symbol and thesaurus for adverse event terminology) terms, physician evaluations of patients, and physical examinations. There were no clinically or statistically significant differences in the frequency of treatment-emergent adverse events or progression of retinopathy, neuropathy, or cardiovascular disease reported with each therapy. There was no difference between insulin lispro and Humulin R in the occurrence and progression of kidney disease as measured by changes in serum creatinine levels. Pooled data from clinical studies show that insulin lispro has a safety profile comparable to that of Humulin R.

 

This article has been cited by other articles:

				B. Ahmad Review: Pharmacology of insulin The British Journal of Diabetes & Vascular Disease, January 1, 2004; 4(1): 10 - 14. [Abstract] [PDF]

				S. Loukovaara, I. Immonen, K. A. Teramo, and R. Kaaja Progression of Retinopathy During Pregnancy in Type 1 Diabetic Women Treated With Insulin Lispro Diabetes Care, April 1, 2003; 26(4): 1193 - 1198. [Abstract] [Full Text] [PDF]